LV11783B - Compositions and methods for stimulating megakaryocyte growth and differentiation - Google Patents
Compositions and methods for stimulating megakaryocyte growth and differentiationInfo
- Publication number
- LV11783B LV11783B LVP-96-369A LV960369A LV11783B LV 11783 B LV11783 B LV 11783B LV 960369 A LV960369 A LV 960369A LV 11783 B LV11783 B LV 11783B
- Authority
- LV
- Latvia
- Prior art keywords
- disclosed
- differentiation
- methods
- growth
- mgdfs
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
- C07K17/02—Peptides being immobilised on, or in, an organic carrier
- C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/524—Thrombopoietin, i.e. C-MPL ligand
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S930/00—Peptide or protein sequence
- Y10S930/01—Peptide or protein sequence
- Y10S930/14—Lymphokine; related peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22176894A | 1994-03-31 | 1994-03-31 | |
US25262894A | 1994-05-31 | 1994-05-31 | |
US08/321,488 US5795569A (en) | 1994-03-31 | 1994-10-12 | Mono-pegylated proteins that stimulate megakaryocyte growth and differentiation |
US34778094A | 1994-11-30 | 1994-11-30 | |
PCT/US1995/003776 WO1995026746A1 (fr) | 1994-03-31 | 1995-03-30 | Compositions et methodes de stimulation de la croissance et de la differentiation des megacaryocytes |
Publications (2)
Publication Number | Publication Date |
---|---|
LV11783A LV11783A (lv) | 1997-06-20 |
LV11783B true LV11783B (en) | 1997-12-20 |
Family
ID=27499246
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LVP-96-369A LV11783B (en) | 1994-03-31 | 1996-10-03 | Compositions and methods for stimulating megakaryocyte growth and differentiation |
LVP-99-17A LV12275B (en) | 1994-03-31 | 1999-02-04 | COMPOSITIONS AND METHODS FOR STIMULATION OF DEGREE AND DIFFERENTIATION OF MEGAKAROCYTE |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LVP-99-17A LV12275B (en) | 1994-03-31 | 1999-02-04 | COMPOSITIONS AND METHODS FOR STIMULATION OF DEGREE AND DIFFERENTIATION OF MEGAKAROCYTE |
Country Status (32)
Country | Link |
---|---|
US (1) | US5766581A (fr) |
EP (3) | EP0755263A4 (fr) |
JP (2) | JP2996415B2 (fr) |
KR (2) | KR100203824B1 (fr) |
CN (2) | CN1103782C (fr) |
AT (1) | ATE169335T1 (fr) |
AU (1) | AU691606B2 (fr) |
BG (1) | BG62685B1 (fr) |
BR (1) | BR9506017A (fr) |
CA (1) | CA2167090C (fr) |
CZ (2) | CZ288926B6 (fr) |
DE (1) | DE69503849T2 (fr) |
DK (1) | DK0690127T3 (fr) |
EE (1) | EE9600121A (fr) |
ES (1) | ES2119250T3 (fr) |
FI (1) | FI960136A (fr) |
GE (1) | GEP20002180B (fr) |
GR (1) | GR3027593T3 (fr) |
HK (2) | HK1004231A1 (fr) |
HU (1) | HU218893B (fr) |
IL (1) | IL113206A0 (fr) |
LV (2) | LV11783B (fr) |
MY (1) | MY113048A (fr) |
NO (1) | NO960111L (fr) |
NZ (1) | NZ283863A (fr) |
PL (1) | PL182567B1 (fr) |
RO (1) | RO115788B1 (fr) |
SI (1) | SI0690127T1 (fr) |
SK (1) | SK166695A3 (fr) |
TW (3) | TW496870B (fr) |
WO (1) | WO1995026746A1 (fr) |
YU (1) | YU20095A (fr) |
Families Citing this family (87)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5824784A (en) * | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
WO1996017062A1 (fr) * | 1994-11-30 | 1996-06-06 | Zymogenetics, Inc. | Thrombopoietine de faible poids moleculaire |
US5986049A (en) * | 1994-12-30 | 1999-11-16 | Zymogenetics, Inc. | Purified thrombopoietin and method of making it |
TW387940B (en) * | 1995-01-17 | 2000-04-21 | Kirin Brewery | Anti-tpo monodonal antibody |
EP0807181A1 (fr) | 1995-02-03 | 1997-11-19 | G.D. Searle & Co. | NOUVEAUX LIGANDS SE FIXANT A c-MPL |
US5989538A (en) * | 1995-02-15 | 1999-11-23 | Amgen Inc. | Mpl ligand analogs |
CA2209298C (fr) * | 1995-02-15 | 2001-12-18 | Amgen Inc. | Analogues de ligand mpl |
US5696250A (en) * | 1995-02-15 | 1997-12-09 | Amgen Inc. | DNA encoding megakaryocyte growth and development factor analogs |
TW434021B (en) * | 1995-03-15 | 2001-05-16 | Kirin Brewery | Methods for preventing adsorption of thrombopoietin (TPO), and stable TPO-containing compositions |
TW434020B (en) * | 1995-03-15 | 2001-05-16 | Kirin Brewery | Methods for preventing adsorption of thrombopoietin (TPO), and stable top-containing compositions |
US5869451A (en) * | 1995-06-07 | 1999-02-09 | Glaxo Group Limited | Peptides and compounds that bind to a receptor |
US6251864B1 (en) | 1995-06-07 | 2001-06-26 | Glaxo Group Limited | Peptides and compounds that bind to a receptor |
EP1961760A3 (fr) | 1995-06-07 | 2008-09-03 | Glaxo Group Limited | Peptides et composés se liant à un récepteur de la thrombopoïétine |
TW497972B (en) * | 1995-06-08 | 2002-08-11 | Kirin Brewery | Stable thrombopoietin (TPO)-containing lyophilized compositions |
US6066318A (en) * | 1995-10-05 | 2000-05-23 | G.D. Searle & Co. | Multi-functional hematopoietic fusion proteins between sequence rearranged C-MPL receptor agonists and other hematopoietic factors |
CA2234059A1 (fr) * | 1995-10-05 | 1997-04-10 | G.D. Searle & Co. | Agoniste du recepteur de c-mpl |
US5879673A (en) * | 1996-01-25 | 1999-03-09 | Genentech, Inc. | Administration of thrombopoietin on a single day only |
US7091311B2 (en) | 1996-06-07 | 2006-08-15 | Smithkline Beecham Corporation | Peptides and compounds that bind to a receptor |
AU4344697A (en) * | 1996-10-04 | 1998-04-24 | Amgen, Inc. | Pharmaceutical compositions containing an mpl ligand |
US5914251A (en) * | 1996-10-22 | 1999-06-22 | Amgen Inc. | Nucleic acid molecules encoding placental-derived growth factors |
AU2006201129B2 (en) * | 1997-05-21 | 2008-03-13 | Genentech, Inc. | Novel administration of thrombopoietin |
AU7589898A (en) * | 1997-05-21 | 1998-12-11 | Genentech Inc. | Novel administration of thrombopoietin |
ES2224649T3 (es) * | 1998-04-28 | 2005-03-01 | Applied Research Systems Ars Holding N.V. | Conjugados de poliol-ifn-beta. |
US20030228666A1 (en) | 1998-06-30 | 2003-12-11 | Daewoong Pharmaceutical Co., Ltd. | Novel human thrombopoietin mutein |
AU773891C (en) | 1998-10-23 | 2005-02-17 | Kirin-Amgen Inc. | Dimeric thrombopoietin peptide mimetics binding to MP1 receptor and having thrombopoietic activity |
US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
US6589759B1 (en) | 1999-03-30 | 2003-07-08 | Trustees Of Boston University | Compositions and methods for producing platelets and/or proplatelets from megakaryocytes |
US20030211094A1 (en) * | 2001-06-26 | 2003-11-13 | Nelsestuen Gary L. | High molecular weight derivatives of vitamin k-dependent polypeptides |
TWI224620B (en) | 2000-08-11 | 2004-12-01 | Kirin Brewery | Polypeptides controlling phosphoric acid metabolism, calcium metabolism, calcification and vitamin D metabolism and DNAS encoding the same |
WO2002015926A1 (fr) * | 2000-08-24 | 2002-02-28 | Kirin Beer Kabushiki Kaisha | Compositions medicinales contenant des ligands c-mpl, destinees a l'augmentation des plaquettes et des erythrocytes |
UY26317A1 (es) * | 2000-08-30 | 2000-10-31 | Alfonso Cayota Carlos Pritsch | Sistema de produccion de trombopoyetina humana por celulas de mamiferos en cultivo |
EP1234583A1 (fr) * | 2001-02-23 | 2002-08-28 | F. Hoffmann-La Roche Ag | Conjugués du PEG et du HGF-NK4 |
US7332474B2 (en) | 2001-10-11 | 2008-02-19 | Amgen Inc. | Peptides and related compounds having thrombopoietic activity |
US20030191056A1 (en) | 2002-04-04 | 2003-10-09 | Kenneth Walker | Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins |
US20040028661A1 (en) * | 2002-08-07 | 2004-02-12 | Bartelmez Stephen H. | Expansion of cells using thrombopoietin and anti-transforming growth factor-beta |
WO2004014938A2 (fr) * | 2002-08-09 | 2004-02-19 | Xencor | Proteines a immunogenicite reduite, stimulant la thrombopoiese |
DK1542714T3 (da) | 2002-09-18 | 2014-05-26 | Janssen Pharmaceuticals Inc | Fremgangsmåder til forøgelse af produktion af blodplader og hæmatopoietiske stamceller |
EP1628618A4 (fr) * | 2002-12-26 | 2009-09-09 | Mountain View Pharmaceuticals | Conjugues polymeres de cytokines, de chimiomokines, de facteurs de croissance, d'hormones polypeptidiques et d'antagonistes de ceux-ci conservant une activite de liaison aux recepteurs |
RS20050502A (en) * | 2002-12-26 | 2007-08-03 | Mountain View Pharmaceuticals Inc., | Polymer conjugates of interferon- beta with enhanced biological potency |
CA2515638A1 (fr) * | 2003-02-11 | 2004-08-26 | Shifeng Pan | Nouveaux composes bicycliques et compositions associees |
US20090123367A1 (en) * | 2003-03-05 | 2009-05-14 | Delfmems | Soluble Glycosaminoglycanases and Methods of Preparing and Using Soluble Glycosaminoglycanases |
US20060104968A1 (en) * | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
ES2335005T5 (es) * | 2003-03-05 | 2013-04-17 | Halozyme, Inc. | Glicoproteína hialuronidasa soluble (shasegp), proceso para prepararla, usos y composiciones farmacéuticas que la comprenden |
AU2004227937B2 (en) * | 2003-03-31 | 2007-09-20 | Xencor, Inc | Methods for rational pegylation of proteins |
US7642340B2 (en) | 2003-03-31 | 2010-01-05 | Xencor, Inc. | PEGylated TNF-α variant proteins |
US7610156B2 (en) * | 2003-03-31 | 2009-10-27 | Xencor, Inc. | Methods for rational pegylation of proteins |
CN102241742B (zh) | 2003-08-28 | 2014-04-02 | 奥索-麦克尼尔药品公司 | 结合血小板生成素受体的肽和化合物 |
US7723295B2 (en) | 2003-08-28 | 2010-05-25 | Ortho-Mcneil Pharmaceutical, Inc. | Peptides and compounds that bind to a receptor |
CA2542353A1 (fr) | 2003-10-10 | 2005-04-21 | Xencor, Inc. | Variants de tnf-alpha a base proteique destines au traitement de troubles associes au tnf-alpha |
DK1699915T3 (da) | 2003-12-30 | 2010-09-13 | Augustinus Bader | Anvendelse af erythropoietin til levervævsregenerering |
WO2005118551A2 (fr) * | 2004-05-28 | 2005-12-15 | Ligand Pharmaceuticals Inc. | Composes modulant l'activite de la thrombopoietine et methodes associees |
US20060018875A1 (en) * | 2004-06-14 | 2006-01-26 | Blatt Lawrence M | Interferon compositions and methods of use thereof |
MX2007000216A (es) | 2004-07-08 | 2007-03-15 | Amgen Inc | Peptidos terapeuticos. |
MX2007000568A (es) * | 2004-07-16 | 2007-03-30 | Nektar Therapeutics Al Corp | Conjugados de una fraccion gm-csf y un polimero. |
AU2005299720B2 (en) | 2004-10-25 | 2010-02-04 | Ligand Pharmaceuticals Incorporated | Thrombopoietin activity modulating compounds and methods |
US8008453B2 (en) | 2005-08-12 | 2011-08-30 | Amgen Inc. | Modified Fc molecules |
WO2007102946A2 (fr) | 2006-01-23 | 2007-09-13 | Amgen Inc. | Polypeptides cristallins |
US7981425B2 (en) | 2006-06-19 | 2011-07-19 | Amgen Inc. | Thrombopoietic compounds |
US8318153B2 (en) * | 2006-06-29 | 2012-11-27 | Nalin David R | Method of medically treating an individual |
AU2008262490B2 (en) | 2007-05-22 | 2011-11-17 | Amgen Inc. | Compositions and methods for producing bioactive fusion proteins |
TWI395593B (zh) | 2008-03-06 | 2013-05-11 | Halozyme Inc | 可活化的基質降解酵素之活體內暫時性控制 |
CA2721229C (fr) | 2008-04-14 | 2022-08-23 | Halozyme, Inc. | Hyaluronidases modifiees et utilisations pour traiter des maladies et des pathologies associees a l'acide hyaluronique |
TWI394580B (zh) | 2008-04-28 | 2013-05-01 | Halozyme Inc | 超快起作用胰島素組成物 |
EA022752B1 (ru) | 2008-12-09 | 2016-02-29 | Галозим, Инк. | Длинные растворимые полипептиды рн20 и их использование |
CN102245675B (zh) | 2008-12-16 | 2013-08-14 | 道康宁公司 | 硅氧烷的制备 |
EP2390261A4 (fr) | 2009-01-20 | 2012-11-14 | Hanall Biopharma Co Ltd | Fragment polypeptidique de thrombopoïétine humaine modifié et son procédé de fabrication |
US8680150B2 (en) * | 2009-05-28 | 2014-03-25 | Ligand Pharmaceuticals, Inc. | Small molecule hematopoietic growth factor mimetic compounds that activate hematopoietic growth factor receptors |
SI3127427T1 (sl) | 2009-05-29 | 2020-07-31 | Novartis Ag | Postopki dajanja spojin agonista trombopoetina |
JP5734985B2 (ja) | 2009-09-17 | 2015-06-17 | バクスター・ヘルスケヤー・ソシエテ・アノニムBaxter Healthcare SA | ヒアルロニダーゼおよび免疫グロブリンの安定な共製剤およびそれらの使用方法 |
WO2011098095A1 (fr) | 2010-02-09 | 2011-08-18 | Aplagen Gmbh | Peptides se liant au récepteur de tpo |
DK2595624T3 (en) | 2010-07-20 | 2018-03-26 | Halozyme Inc | Methods of treating or preventing adverse side effects associated with administration of an anti-hyaluronan agent |
JP2014510045A (ja) | 2011-02-08 | 2014-04-24 | ハロザイム インコーポレイテッド | ヒアルロナン分解酵素の組成物および脂質製剤ならびに良性前立腺肥大症の治療のためのその使用 |
KR101676543B1 (ko) | 2011-06-17 | 2016-11-15 | 할로자임, 아이엔씨 | 히알루로난 분해효소를 이용한 연속적인 피하 인슐린 주입 방법 |
US9993529B2 (en) | 2011-06-17 | 2018-06-12 | Halozyme, Inc. | Stable formulations of a hyaluronan-degrading enzyme |
WO2013040501A1 (fr) | 2011-09-16 | 2013-03-21 | Pharmathene, Inc. | Compositions et combinaisons d'accepteurs biologiques organophosphorés et d'enzymes dégradant le hyaluronane, et leurs utilisations |
EP2771028A2 (fr) | 2011-10-24 | 2014-09-03 | Halozyme, Inc. | Diagnostic compagnon pour le traitement avec un agent anti-hyaluronane et procédés d'utilisation dudit diagnostic |
DK3130347T3 (da) | 2011-12-30 | 2019-10-14 | Halozyme Inc | PH20-polypeptidvarianter, formuleringer og anvendelser deraf |
AU2013243873B2 (en) | 2012-04-04 | 2016-08-25 | Halozyme, Inc. | Combination therapy with an anti - hyaluronan agent and a tumor - targeted taxane |
WO2014062856A1 (fr) | 2012-10-16 | 2014-04-24 | Halozyme, Inc. | Hypoxie et hyaluronane et leurs marqueurs pour le diagnostic et la surveillance de maladies et de pathologies, et méthodes associées |
TW201534726A (zh) | 2013-07-03 | 2015-09-16 | Halozyme Inc | 熱穩定ph20玻尿酸酶變異體及其用途 |
HUE043847T2 (hu) | 2014-08-28 | 2019-09-30 | Halozyme Inc | Hialuronán-lebontó enzimmel és egy immun checkpoint inhibitorral végzett kombinációs terápia |
DK3207130T3 (da) | 2014-10-14 | 2019-11-11 | Halozyme Inc | Sammensætninger af Adenosin Deaminase-2 (ADA2), varianter deraf og fremgangsmåder til anvendelse af samme |
KR102675270B1 (ko) | 2017-06-22 | 2024-06-17 | 버텍스 파마슈티칼스 인코포레이티드 | 변형된 막 유형 세린 프로테아제 1(mtsp-1) 폴리펩티드 및 사용 방법 |
WO2019222435A1 (fr) | 2018-05-16 | 2019-11-21 | Halozyme, Inc. | Procédés de sélection de sujets pour une polythérapie anticancéreuse avec un ph20 soluble conjugué à un polymère |
AU2019413431A1 (en) | 2018-12-28 | 2021-07-08 | Vertex Pharmaceuticals Incorporated | Modified urokinase-type plasminogen activator polypeptides and methods of use |
US11613744B2 (en) | 2018-12-28 | 2023-03-28 | Vertex Pharmaceuticals Incorporated | Modified urokinase-type plasminogen activator polypeptides and methods of use |
Family Cites Families (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) * | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US4002531A (en) * | 1976-01-22 | 1977-01-11 | Pierce Chemical Company | Modifying enzymes with polyethylene glycol and product produced thereby |
JPS6023084B2 (ja) * | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
US4640835A (en) * | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
DE3380726D1 (en) * | 1982-06-24 | 1989-11-23 | Japan Chem Res | Long-acting composition |
EP0154316B1 (fr) * | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Lymphokine chimiquement modifiée et son procédé de préparation |
DE3675588D1 (de) * | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
US4810643A (en) * | 1985-08-23 | 1989-03-07 | Kirin- Amgen Inc. | Production of pluripotent granulocyte colony-stimulating factor |
US4894440A (en) * | 1986-09-17 | 1990-01-16 | Massachusetts Institute Of Technology | Method of isolating megakaryocyte stimulatory factor |
ZA887773B (en) * | 1987-10-26 | 1989-07-26 | Immunex Corp | Interleukin-7 |
US4904584A (en) * | 1987-12-23 | 1990-02-27 | Genetics Institute, Inc. | Site-specific homogeneous modification of polypeptides |
US4847325A (en) * | 1988-01-20 | 1989-07-11 | Cetus Corporation | Conjugation of polymer to colony stimulating factor-1 |
CA1340810C (fr) * | 1988-03-31 | 1999-11-02 | Motoo Yamasaki | Derives de polypeptides actifs comme facteurs stimulant les colonies de granulocytes chez l'homme |
IL90719A0 (en) * | 1988-06-28 | 1990-01-18 | Yissum Res Dev Co | Novel nuclei acids and polypeptides encoded thereby |
US5128449A (en) * | 1988-07-05 | 1992-07-07 | The University Of Tennessee Research Corporation | Polypeptide and a method for its production |
EP0516845B1 (fr) * | 1988-09-21 | 1997-06-18 | Meiji Seika Kaisha Ltd. | Nouveau facteur de stimulation de colonies megakaryocytiques et procede de preparation |
GB8824591D0 (en) * | 1988-10-20 | 1988-11-23 | Royal Free Hosp School Med | Fractionation process |
ATE135370T1 (de) * | 1988-12-22 | 1996-03-15 | Kirin Amgen Inc | Chemisch modifizierte granulocytenkolonie erregender faktor |
US5087448A (en) * | 1989-02-02 | 1992-02-11 | The Board Of Regents Of The University Of Oklahoma | Enhancing growth of megakaryocytes in mammals using interleuking 6 |
US5032396A (en) * | 1989-02-17 | 1991-07-16 | Immunex Corporation | IL-7 to stimulate platelet production |
WO1990012108A1 (fr) * | 1989-04-03 | 1990-10-18 | Genetics Institute, Inc. | Activite favorisant la croissance de megacaryocytes |
US5260417A (en) * | 1989-04-03 | 1993-11-09 | Genetics Institute, Inc. | Megakaryocyte growth promoting activity protein |
WO1990012877A1 (fr) * | 1989-04-19 | 1990-11-01 | Cetus Corporation | Proteines m-csf multifonctionnelles et codage de genes pour celles-ci |
US6433142B1 (en) * | 1989-08-08 | 2002-08-13 | Genetics Institute, Llc | Megakaryocyte stimulating factors |
HUT63441A (en) * | 1989-08-08 | 1993-08-30 | Genetics Inst | Megakariocyte colony stimultating factor protein |
US5215895A (en) * | 1989-11-22 | 1993-06-01 | Genetics Institute, Inc. | Dna encoding a mammalian cytokine, interleukin-11 |
JPH04218000A (ja) * | 1990-02-13 | 1992-08-07 | Kirin Amgen Inc | 修飾ポリペプチド |
CA2084074A1 (fr) * | 1990-05-31 | 1991-12-01 | Keita Matsunaga | Facteur de stimulation de colonies de megacaryocytes |
EP0540575A4 (en) * | 1990-07-02 | 1994-06-08 | Hipple Cancer Res Center | Human meg-csf protein and methods |
IE912365A1 (en) * | 1990-07-23 | 1992-01-29 | Zeneca Ltd | Continuous release pharmaceutical compositions |
KR927003795A (ko) * | 1990-10-05 | 1992-12-18 | 시스테믹스, 인코포레이티드 | 거핵세포 및 혈소판 성장, 제조방법 및 이것들을 포함하는 조성물 |
JPH05503302A (ja) * | 1990-10-12 | 1993-06-03 | アムジエン・インコーポレーテツド | 巨核球成熟因子 |
WO1992007074A1 (fr) * | 1990-10-19 | 1992-04-30 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Polypeptide de la famille d'un recepteur de facteur de croissance, application au diagnostic et a la therapie des maladies myeloproliferatives |
AU646530B2 (en) * | 1990-12-28 | 1994-02-24 | Asahi Kasei Kogyo Kabushiki Kaisha | Novel megakaryocyte amplifier and production thereof |
JP3283288B2 (ja) * | 1991-03-08 | 2002-05-20 | 電気化学工業株式会社 | 生理活性ペプチド製剤 |
JPH04295500A (ja) * | 1991-03-26 | 1992-10-20 | Asahi Chem Ind Co Ltd | 新規な巨核球増幅因子とその製法 |
WO1993000109A1 (fr) * | 1991-06-28 | 1993-01-07 | Genentech, Inc. | Procede de stimulation de la reponse immunitaire a l'aide d'hormone de croissance |
AU2296992A (en) * | 1991-06-28 | 1993-01-25 | New England Deaconess Hospital | A differentiated megakaryocyte line producing novel megakaryocyte differentiation factors |
US5250732A (en) * | 1991-07-18 | 1993-10-05 | Genentech, Inc. | Ketamine analogues for treatment of thrombocytopenia |
NZ244778A (en) * | 1991-10-21 | 1994-03-25 | Ortho Pharma Corp | Peg imidates and protein derivatives thereof |
JP3328341B2 (ja) * | 1991-12-27 | 2002-09-24 | 中外製薬株式会社 | 新規な巨核球増幅因子 |
AU3463493A (en) * | 1992-02-07 | 1993-09-03 | Asahi Kasei Kogyo Kabushiki Kaisha | Novel megakaryocyte amplifier and production thereof |
AU4190893A (en) * | 1992-07-17 | 1994-01-20 | Suntory Limited | Megakaryocyte differentiation factor |
SG47030A1 (en) * | 1994-01-03 | 1998-03-20 | Genentech Inc | Thrombopoietin |
SG79882A1 (en) * | 1994-02-14 | 2001-04-17 | Kirin Brewery | Protein having tpo activity |
PL178384B1 (pl) * | 1994-02-14 | 2000-04-28 | Univ Washington | Wydzielone białko, wydzielone cząsteczki polinukleotydowe, wektor ekspresji, hodowana komórka, kompozycja farmaceutyczna do stymulacji wytwarzania płytek krwi u ssaka, sposób wytwarzania białka homeopoezyjnego, sposób otrzymywania przeciwciał, sposób stymulacji i namnażania komórek |
WO1995021919A2 (fr) * | 1994-02-14 | 1995-08-17 | Kirin Brewery Company, Limited | Proteine a activite de thrombopoietine (tpo) |
CA2169173C (fr) * | 1994-02-14 | 2002-10-15 | Kenneth Kaushansky | Procede de stimulation de l'erythropoiese a l'aide de proteines hematopoietiques |
US5547931A (en) * | 1994-02-23 | 1996-08-20 | Immtech International Inc. | Methods of stimulatory thrombocytopoiesis using modified C-reactive protein |
US5571686A (en) * | 1994-04-14 | 1996-11-05 | Massachusetts Institute Of Technology | Method of using megapoietin for prolonging the survival & viability of platlets |
-
1995
- 1995-03-30 WO PCT/US1995/003776 patent/WO1995026746A1/fr not_active Application Discontinuation
- 1995-03-30 CA CA002167090A patent/CA2167090C/fr not_active Expired - Fee Related
- 1995-03-30 YU YU20095A patent/YU20095A/sh unknown
- 1995-03-30 CN CN95190628A patent/CN1103782C/zh not_active Expired - Fee Related
- 1995-03-30 KR KR1019960700308A patent/KR100203824B1/ko not_active IP Right Cessation
- 1995-03-30 TW TW085116057A patent/TW496870B/zh not_active IP Right Cessation
- 1995-03-30 US US08/413,803 patent/US5766581A/en not_active Expired - Fee Related
- 1995-03-30 DK DK95104745T patent/DK0690127T3/da active
- 1995-03-30 ES ES95104745T patent/ES2119250T3/es not_active Expired - Lifetime
- 1995-03-30 RO RO96-00063A patent/RO115788B1/ro unknown
- 1995-03-30 EE EE9600121A patent/EE9600121A/xx unknown
- 1995-03-30 TW TW084103273A patent/TW414799B/zh not_active IP Right Cessation
- 1995-03-30 TW TW088113115A patent/TW565568B/zh not_active IP Right Cessation
- 1995-03-30 CN CNB011166304A patent/CN1229385C/zh not_active Expired - Fee Related
- 1995-03-30 DE DE69503849T patent/DE69503849T2/de not_active Expired - Fee Related
- 1995-03-30 EP EP95915425A patent/EP0755263A4/fr not_active Withdrawn
- 1995-03-30 CZ CZ19953505A patent/CZ288926B6/cs not_active IP Right Cessation
- 1995-03-30 AT AT95104745T patent/ATE169335T1/de not_active IP Right Cessation
- 1995-03-30 SI SI9530160T patent/SI0690127T1/xx not_active IP Right Cessation
- 1995-03-30 GE GEAP19953368A patent/GEP20002180B/en unknown
- 1995-03-30 KR KR1019980710986A patent/KR100303810B1/ko not_active IP Right Cessation
- 1995-03-30 AU AU22308/95A patent/AU691606B2/en not_active Ceased
- 1995-03-30 EP EP95104711A patent/EP0675201A1/fr not_active Withdrawn
- 1995-03-30 HU HU9600059A patent/HU218893B/hu not_active IP Right Cessation
- 1995-03-30 SK SK1666-95A patent/SK166695A3/sk unknown
- 1995-03-30 BR BR9506017A patent/BR9506017A/pt not_active Application Discontinuation
- 1995-03-30 JP JP7525783A patent/JP2996415B2/ja not_active Expired - Fee Related
- 1995-03-30 EP EP95104745A patent/EP0690127B1/fr not_active Expired - Lifetime
- 1995-03-31 MY MYPI95000831A patent/MY113048A/en unknown
- 1995-03-31 IL IL11320695A patent/IL113206A0/xx unknown
-
1996
- 1996-01-10 NO NO960111A patent/NO960111L/no not_active Application Discontinuation
- 1996-01-11 FI FI960136A patent/FI960136A/fi not_active IP Right Cessation
- 1996-03-12 PL PL95312577A patent/PL182567B1/pl not_active IP Right Cessation
- 1996-03-12 NZ NZ283863A patent/NZ283863A/en unknown
- 1996-05-30 BG BG100625A patent/BG62685B1/bg unknown
- 1996-10-03 LV LVP-96-369A patent/LV11783B/xx unknown
-
1998
- 1998-04-23 HK HK98103418A patent/HK1004231A1/xx not_active IP Right Cessation
- 1998-08-06 GR GR980401561T patent/GR3027593T3/el unknown
-
1999
- 1999-02-04 LV LVP-99-17A patent/LV12275B/en unknown
- 1999-08-18 JP JP23173099A patent/JP3485842B2/ja not_active Expired - Fee Related
-
2000
- 2000-04-03 CZ CZ20001203A patent/CZ288890B6/cs not_active IP Right Cessation
-
2002
- 2002-04-24 HK HK02103111.6A patent/HK1041275B/zh not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1004231A1 (en) | Compositions and methods for stimulating megakaryocyte growth and differentiation | |
Munksgaard et al. | Collagen synthesis and secretion by rat incisor odontoblasts in organ culture | |
MX9602259A (es) | Proteina modificada quimicamente en el nitrogeno terminal, composiciones que las incluyen y metodos para su preparacion. | |
ATE147436T1 (de) | Menschliches cytokin, interleukin-9 | |
ATE82495T1 (de) | Verfahren zur herstellung pharmazeutischer mischungen. | |
GB2344519B (en) | Sterile therapeutic compositions | |
ATE330003T1 (de) | Rekombinanter stabiler zellklon, seine herstellung und verwendung | |
WO1997023507A3 (fr) | Nouvelle forme d'amphireguline, ses procedes de production et son utilisation ainsi que compositions la contenant | |
DE69032471D1 (de) | Proteine mit onkostatin-m-aktivität und verfahren zu ihrer herstellung | |
ES8705466A1 (es) | Un metodo para la preparacion del factor nkbs regulador del cancer humano. | |
DE69022121D1 (de) | Verfahren zur Herstellung eines Metastaseninhibitorenfaktors. | |
ES2004438A6 (es) | Un metodo para producir una proteina trombolitica |